This review discusses the evidence in support of the use of afatinib, its pharmacology including its mechanism of action, and efficacy and tolerability as demonstrated in pivotal clinical trials. It also provides commentary and recommendations from Professor Ken O’Byrne, a Consultant and Professor in Medical Oncology recently moved to the Princess Alexandra Hospital.
Please login below to download this issue (PDF)